Suppressive Effect of Pioglitazone, a PPAR Gamma Ligand, on Azoxymethane-induced Colon Aberrant Crypt Foci in KK-Aу Mice

  • Ueno, Toshiya (Division of Cancer Prevention Research, National Cancer Center Research Institute) ;
  • Teraoka, Naoya (Division of Cancer Prevention Research, National Cancer Center Research Institute) ;
  • Takasu, Shinji (Division of Cancer Prevention Research, National Cancer Center Research Institute) ;
  • Nakano, Katsuya (Division of Cancer Prevention Research, National Cancer Center Research Institute) ;
  • Takahashi, Mami (Central Animal Division, National Cancer Center Research Institute) ;
  • Yamamoto, Masafumi (Central Animal Division, National Cancer Center Research Institute) ;
  • Fujii, Gen (Division of Cancer Prevention Research, National Cancer Center Research Institute) ;
  • Komiya, Masami (Division of Cancer Prevention Research, National Cancer Center Research Institute) ;
  • Yanaka, Akinori (Faculty of Pharmaceutical Sciences, Tokyo University of Science) ;
  • Wakabayashi, Keiji (Graduate School of Integrated Pharmaceutical and Nutritional Sciences, University of Shizuoka) ;
  • Mutoh, Michihiro (Division of Cancer Prevention Research, National Cancer Center Research Institute)
  • Published : 2012.08.31


Obesity is an established risk factor for colorectal cancer. Pioglitazone is a peroxisome proliferator activated receptor$receptor{\gamma}$ ($PPAR{\gamma}$) agonist that induces differentiation in adipocytes and induces growth arrest and/or apoptosis in vitro in several cancer cell lines. In the present study, we investigated the effect of pioglitazone on the development of azoxymethane-induced colon aberrant crypt foci (ACF) in KK-$A^{\mathcal{Y}}$ obesity and diabetes model mice, and tried to clarify mechanisms by which the $PPAR{\gamma}$ ligand inhibits ACF development. Administration of 800 ppm pioglitazone reduced the number of colon ACF/mouse to 30% of those in untreated mice and improved hypertrophic changes of adipocytes in KK-$A^{\mathcal{Y}}$ mice with significant reduction of serum triglyceride and insulin levels. Moreover, mRNA levels of adipocytokines, such as leptin, monocyte chemoattractant protein-1 and plasminogen activator inhibitor-1, in the visceral fat were decreased. PCNA immunohistochemistry revealed that pioglitazone treatment suppressed cell proliferation in the colorectal epithelium with elevation of p27 and p53 gene expression. These results suggest that pioglitazone prevented obesity-associated colon carcinogenesis through improvement of dysregulated adipocytokine levels and high serum levels of triglyceride and insulin, and increase of p27 and p53 mRNA levels in the colorectal mucosa. These data indicate that pioglitazone warrants attention as a potential chemopreventive agent against obesity-associated colorectal cancer.


  1. Bird RP (1987). Observation and quantification of aberrant crypts in the murine colon treated with a colon carcinogen: preliminary findings. Cancer Letts, 37, 147-51.
  2. Bojková B, Garajova M, Kajo K, et al (2010). Pioglitazone in chemically induced mammary carcinogenesis in rats. Eur J Cancer Prev, 19, 379-84.
  3. Bruce WR, Wolever TM, Giacca A (2000). Mechanisms linking diet and colorectal cancer: the possible role of insulin resistance. Nutr Cancer, 37, 19-26.
  4. Cowey S, Hardy RW (2006). The metabolic syndrome: A high-risk state for cancer? Am J Pathol, 169, 1505-22.
  5. Ferrara A, Lewis JD, Quesenberry CP Jr, et al (2011). Cohort study of pioglitazone and cancer incidence in patients with diabetes. Diabetes Care, 34, 923-9.
  6. Fisher B, Costantino JP, Wickerham DL, et al (1998). Tamoxifen for prevention of breast cancer: report of the national surgical adjuvant breast and bowel project P-1 study. J Natl Cancer Inst, 90, 1371-88.
  7. Fukada T, Ohtani T, Yoshida Y, et al (1998). STAT3 orchestrates contradictory signals in cytokine-induced G1 to S cell-cycle transition. EMBO J, 17, 6670-7.
  8. Ikeda H, Taketomi S, Sugiyama Y, et al (1990). Effects of pioglitazone on glucose and lipid metabolism in normal and insulin resistant animals. Arzneimittelforschung, 40, 156-62.
  9. Itami A, Watanabe G, Shimada-Itami A, et al (2001). Ligands for peroxisome proliferator-activated receptorγ inhibit growth of pancreatic cancers both in vitro and in vivo. Int J Cancer, 94, 370-6.
  10. Iwaki M, Matsuda M, Maeda N, et al (2003). Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors. Diabetes, 52, 1655-63.
  11. Kortylewski M, Heinrich PC, Mackiewicz A, et al (1999). Interleukin-6 and oncostatin M-induced growth inhibition of human A375 melanoma cells is STAT-dependent and involves upregulation of the cyclin-dependent kinase inhibitor p27/Kip1. Oncogene, 18, 3742-53.
  12. Le Marchand L, Wilkens LR, Kolonel LN, et al (1997). Association of sedentary lifestyle, obesity, smoking, alcohol use, and diabetes with the risk of colorectal cancer. Cancer Res, 57, 4787-94.
  13. Nakamura M, Yamada K (1967). Studies on a diabetic (KK) strain of the mouse. Diabetologia, 3, 212-21.
  14. Niho N, Mutoh M, Takahashi M, et al (2005). Concurrent suppression of hyperlipidemia and intestinal polyp formation by NO-1886, increasing lipoprotein lipase activity in Min mice. Proc Natl Acad Sci USA, 102, 2970- 4.
  15. Niho N, Takahashi M, Shoji Y, et al (2003). Dose-dependent suppression of hyperlipidemia and intestinal polyp formation in Min mice by pioglitazone, a PPARγ ligand. Cancer Sci, 94, 960-64.
  16. Polyak K, Kato JY, Solomon MJ, et al (1994). p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factorbeta and contact inhibition to cell cycle arrest. Genes Dev, 8, 9-22.
  17. Rumi MA, Sato H, Ishihara S, et al (2002). Growth inhibition of esophageal squamous carcinoma cells by peroxisome proliferator-activated receptor ${\gamma}$ ligands. J Lab Clin Med, 140, 17-26.
  18. Sakamoto J, Kimura H, Moriyama S, et al (2000). Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone. Biochem Biophys Res Commun, 278, 704-11.
  19. Schoonjans K, Peinado-Onsurbe J, Lefebvre AM, et al (1996). PPARalpha and PPARgammma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J, 15, 5336-48.
  20. Schoonjans K, Staels B, Auwerx J (1996). The peroxisome proliferator activated receptors (PPARs) and their effects on lipid metabolism and adipocyte differentiation. Biochim Biophys Acta, 1302, 93-109.
  21. Shah P, Mudaliar S (2010). Pioglitazone: side effect and safety profile. Expert Opin Drug Saf, 9, 347-54.
  22. Shimada T, Kojima K, Yoshiura K, et al (2002). Characteristics of the peroxisome proliferators activated receptor gamma (PPAR gamma) ligand induced apoptosis in colon cancer cells. Gut, 50, 658-64.
  23. Sohda T, Momose Y, Meguro K, et al (1990). Studies on antidiabetic agents. Synthesis of hypoglycemic activity of 5-[4-(pyridylalkoxy)benzyl]-2,4-thiazolidinediones. Arzneimittelforschung, 40, 37-42.
  24. Sporn MB, Suh N (2000). Chemoprevention of cancer. Carcinogenesis, 21, 525-30.
  25. Takahashi N, Okumura T, Motomura W, et al (1999). Activation of PPARγ inhibits cell growth and induces apoptosis in human gastric cancer cells. FEBS Lett, 455, 135-9.
  26. Teraoka N, Mutoh M, Takasu S, et al (2011). High susceptibility to azoxymethane-induced colorectal carcinogenesis in obese KK-Ay Mice. Int J Cancer, 102, 79-87.
  27. Turmelle YP, Shikapwashya O, Tu S, et al (2006). Rosiglitazone inhibits mouse liver regeneration. FASEB J, 20, 2609-11.
  28. van Kruijsdijk RC, van der Wall E, Visseren FL (2009). Obesity and cancer: the role of dysfunctional adipose tissue. Cancer Epidemiol Biomarkers Prev, 18, 2569-78.
  29. Xiao X, Wang Y, Gong H, et al (2009). Molecular evidence of senescence in corneal endothelial cells of senescenceaccelerated mice. Mol Vis, 15, 747-61.

Cited by

  1. allele promotes azoxymethane-induced colorectal carcinogenesis by macrophage migration in hyperlipidemic/diabetic KK mice vol.104, pp.7, 2013,
  2. Type II Diabetes, Metformin Use, and Colorectal Neoplasia: Mechanisms of Action and Implications for Future Research vol.10, pp.1, 2014,
  3. Ubiquitination of p53 is Involved in Troglitazone Induced Apoptosis in Cervical Cancer Cells vol.15, pp.5, 2014,
  4. Pioglitazone, a PPARγ agonist, inhibits growth and invasion of human hepatocellular carcinoma via blockade of the rage signaling vol.54, pp.12, 2014,
  5. Unexploited Antineoplastic Effects of Commercially Available Anti-Diabetic Drugs vol.9, pp.2, 2016,